Hamburg, April 1st, 2021 altona Diagnostics GmbH, today announced the launch of the AltoStar® HIV RT-PCR Kit 1.5, an in vitro diagnostic test, based on real-time RT-PCR technology, for the detection and quantification of human immunodeficiency virus type 1 (HIV-1) specific RNA (groups M, N and O) in human EDTA plasma.

Hamburg, April 30th 2020, altona Diagnostics GmbH announced today the launch of the CE-IVD marked RealStar® SARS-CoV-2 RT-PCR Kit 1.0 an in vitro diagnostic test, based on real-time PCR technology, for the qualitative detection of lineage B-beta coronavirus (lineage B-βCoV) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) specific RNA. It is intended to be used as an aid for diagnosis in individuals with signs and symptoms of coronavirus disease 2019 (COVID-19) in conjunction with clinical and epidemiological risk factors.

Hamburg, February 20, 2020, altona Diagnostics GmbH, today announced the launch of the RealStar® SARS-CoV-2 RT-PCR Kit 1.0. The assay is based on real-time RT-PCR technology, for the detection of SARS-CoV-2 (previously 2019-nCoV) which is the causative agent of coronavirus disease 2019 (COVID-19).

Hamburg, February 07, 2019 altona Diagnostics GmbH, today announced the launch of the AltoStar® HCV RT-PCR Kit 1.5, an in vitro diagnostic test, based on real-time RT-PCR technology, for the detection and quantification of hepatitis C virus (HCV) specific RNA (genotypes 1 to 6). Read more

altona Diagnostics Brasil LTDA, São Paulo, the Brazilian subsidiary of the German infectious disease specialist altona Diagnostics GmbH (altona), Hamburg, got registration approval of ANVISA for its real-time PCR kit to detect RNA of Zika virus in human sample material.

altona Diagnostics celebrates the launch of the AltoStar® Molecular Diagnostic Workflow.The recently developed CE-IVD marked system will be shown at the ECCMID 2018 which will take place in Madrid, Spain, from 21 – 24 April 2018.